STOCK TITAN

MariMed (MRMD) awards director 75,000 RSUs vesting in one year

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Gildea Edward J reported acquisition or exercise transactions in this Form 4 filing.

MariMed Inc. director Edward J. Gildea reported new equity compensation. On June 4, 2026, he was granted 75,000 Restricted Stock Units (RSUs), each convertible into one share of common stock. The RSUs vest in full one year from the grant date. Following this filing, he directly holds 905,208 shares of common stock and a separate award of 75,000 RSUs.

Positive

  • None.

Negative

  • None.
Insider Gildea Edward J
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Units (RSU) 75,000 $0.00 --
holding Common stock -- -- --
Holdings After Transaction: Restricted Stock Units (RSU) — 75,000 shares (Direct, null); Common stock — 905,208 shares (Direct, null)
Footnotes (1)
  1. RSUs convert to shares of common stock on a one-for-one basis. The RSUs will vest in full one year from the date of grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person.
RSU grant size 75,000 RSUs Granted to Edward J. Gildea on June 4, 2026
RSU conversion ratio 1 RSU = 1 share RSUs convert into common stock on a one-for-one basis
RSU vesting schedule 1 year RSUs vest in full one year from grant date
Common shares held 905,208 shares Directly owned MariMed common stock after transactions
Derivative holdings after grant 75,000 RSUs Total RSUs held by Edward J. Gildea after reported grant
Restricted Stock Units (RSU) financial
"The RSUs will vest in full one year from the date of grant"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
one-for-one basis financial
"RSUs convert to shares of common stock on a one-for-one basis"
vest in full financial
"The RSUs will vest in full one year from the date of grant"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gildea Edward J

(Last)(First)(Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD MASSACHUSETTS 02062

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common stock905,208D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units (RSU)(1)06/04/2026A75,000 (2) (2)Common Stock, par value $.001 per share75,000$075,000D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. The RSUs will vest in full one year from the date of grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person.
Remarks:
The RSUs represent the annual equity grant under the Issuer's non-employee director compensation program.
/s/ Edward Gildea06/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MariMed (MRMD) report for Edward J. Gildea?

MariMed director Edward J. Gildea reported receiving 75,000 restricted stock units on June 4, 2026. These RSUs are a grant or award and represent additional equity-based compensation tied to the company’s common stock.

How many RSUs did MariMed (MRMD) grant to Edward J. Gildea and how do they convert?

MariMed granted Edward J. Gildea 75,000 Restricted Stock Units (RSUs). According to the filing, each RSU converts into one share of MariMed common stock, giving him rights to 75,000 future shares upon vesting and settlement.

When do Edward J. Gildea’s 75,000 MariMed (MRMD) RSUs vest?

The 75,000 RSUs granted to Edward J. Gildea vest in full one year from the June 4, 2026 grant date. Vesting is governed by the award agreement between MariMed and Gildea described in the Form 4 footnotes.

How many MariMed (MRMD) common shares does Edward J. Gildea hold after this Form 4?

After the reported transactions, Edward J. Gildea directly holds 905,208 shares of MariMed common stock. This figure reflects his direct ownership position following the RSU grant reported in the Form 4 filing.

Did Edward J. Gildea buy or sell MariMed (MRMD) shares in this Form 4?

The Form 4 does not show any open-market purchases or sales of MariMed shares by Edward J. Gildea. It reports a grant of 75,000 Restricted Stock Units and a holdings entry for his 905,208 directly owned common shares.

What type of security are the RSUs reported for MariMed (MRMD) director Edward J. Gildea?

The reported award consists of Restricted Stock Units (RSUs) tied to MariMed common stock. Each RSU represents the right to receive one share of common stock, subject to vesting conditions described in the related award agreement.